Innovent Biologics (IVBXF) News Today → Never use this word on your phone (FBI could be watching) (From Paradigm Press) (Ad) Free IVBXF Stock Alerts $5.42 +0.04 (+0.74%) (As of 05/3/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartHeadlinesShort InterestStock AnalysisAnalyst ForecastsChartHeadlinesShort Interest All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative SourceHeadlineInnovent Announces the Appointment of Dr. Samuel Zhang as Global Chief Business Officer (CBO)prnewswire.com - April 30 at 12:30 AMInnovent to Present Clinical Data of Multiple Novel Molecules at the 2024 ASCO Annual Meetingprnewswire.com - April 24 at 9:59 PMInnovent Biologics Inc IVBXFmorningstar.com - April 17 at 3:02 PMInnovent Announces the Appointment of Dr. Nageatte Ibrahim as the Oncology Chief Medical Officer (CMO)prnewswire.com - April 15 at 8:00 PMInnovent to Present Preclinical Data of Multiple Novel Molecules at the 2024 AACR Annual Meetingprnewswire.com - April 7 at 8:00 PMInnovent Biologics: A Strong Buy on Robust Sales Growth and Promising Pipelinemarkets.businessinsider.com - April 2 at 11:19 AMInnovent and HUTCHMED Jointly Announce NDA Acceptance in China for Sintilimab Combination with Fruquintinib for the Treatment of Advanced Endometrial Cancer with Priority Review Statusfinance.yahoo.com - April 2 at 11:19 AMInnovent Dosed First Participant in Phase 3 Clinical Study (Neoshot) of IBI310 (Anti-CTLA-4 Monoclonal Antibody) in Combination with Sintilimab for MSI-H/dMMR Colon Cancer Neoadjuvant Therapyprnewswire.com - March 26 at 8:00 PMInnovent Biologics: A Buy Rating on Strong Sales, Improved Efficiency, and Promising Pipelinemarkets.businessinsider.com - March 25 at 4:52 AMInnovent Announces 2023 Annual Results and Business Updatesprnewswire.com - March 20 at 7:41 AMInnovent Announces Primary Endpoint Met in the Second Phase 2 Clinical Trial of IBI302 (anti-VEGF/complement) in Treating Neovascular Age-related Macular Degeneration (nAMD)prnewswire.com - March 18 at 8:00 PMInnovent to Present Preclinical Data of Multiple Novel Molecules at the 2024 AACR Annual Meetingfinance.yahoo.com - March 11 at 8:08 PMInnovent to Present Preclinical Data of Multiple Novel Molecules at the 2024 AACR Annual Meetingprnewswire.com - March 11 at 8:00 PMInnovent released the results of two clinical studies of IBI311 (an anti-IGF-1R monoclonal antibody) in oral presentations at the Asia-Pacific Academy of Ophthalmology Congress and International Congress of Endocrinology 2024prnewswire.com - March 6 at 10:41 PMInnovent and AnHeart Therapeutics Announce the NMPA of China Has Accepted Second NDA for Taletrectinib for First-Line Treatment of ROS1-Positive Lung Cancerprnewswire.com - March 5 at 12:32 AMAnHeart Therapeutics and Innovent Announce China's NMPA has Accepted Second New Drug Application for Taletrectinib for First-Line Treatment of ROS1-Positive Lung Cancerbusinesswire.com - March 4 at 11:00 PMWeek In Review: Mabwell Sells Ex-China Rights To Rare Disease Therapy In $412M Dealseekingalpha.com - March 3 at 2:35 AMInnovent Biologics : Phase 3 Study Of IBI311 In Thyroid Eye Disease Meets Primary Endpointnasdaq.com - February 19 at 10:51 PMInnovent Announces Primary Endpoint Met in the Phase 3 Clinical Trial (RESTORE-1) of IBI311 (Anti-IGF-1R Antibody) in Treating Thyroid Eye Disease and Plans to Submit NDA to the NMPAfinance.yahoo.com - February 19 at 10:51 PMInnovent Announces Primary Endpoint Met in the Phase 3 Clinical Trial (RESTORE-1) of IBI311 (Anti-IGF-1R Antibody) in Treating Thyroid Eye Disease and Plans to Submit NDA to the NMPAprnewswire.com - February 19 at 7:21 PMInnovent's First New Drug Application of Mazdutide for Chronic Weight Management has been Accepted by the NMPA of Chinafinance.yahoo.com - February 7 at 3:53 AMInnovent Biologics announces CFO transitionmsn.com - February 5 at 8:34 AMInnovent Biologics Names Fei You New CFOmarkets.businessinsider.com - February 5 at 8:34 AMInnovent Announces Retirement of CFO and Appointment of New CFOfinance.yahoo.com - February 5 at 8:34 AMInnovent Announces the First Phase 3 Clinical Trial of Mazdutide in Chinese Adults with Overweight or Obesity Met the Primary and All Key Secondary Endpoints, and Plans to Submit NDA of Mazdutide to the NMPAfinance.yahoo.com - January 9 at 12:07 AMIVBXF Innovent Biologics, Inc.seekingalpha.com - January 4 at 6:25 PMInnovent Dosed First Participant in Phase 3 Clinical Study (GLORY-2) of Mazdutide (IBI362) Higher Dose 9 mg in Chinese Adults with Obesityfinance.yahoo.com - January 1 at 7:23 PMAnalysts Offer Insights on Healthcare Companies: Trulieve Cannabis (OtherTCNNF), Roche Holding AG (OtherRHHVF) and Innovent Biologics (OtherIVBXF)markets.businessinsider.com - December 29 at 8:16 PMInnovent Biologics, Xuanzhu collaborate on clinical trial for advanced solid tumors in Chinamsn.com - December 28 at 7:43 AMInnovent and Xuanzhu Enter into Clinical Trial Collaboration Investigating Combination Therapy of Sintilimab (PD-1 inhibitor) and A Novel ADC Candidate for Advanced Solid Tumors in Chinafinance.yahoo.com - December 27 at 8:09 PMJefferies Reaffirms Their Buy Rating on Innovent Biologics (IVBXF)markets.businessinsider.com - December 26 at 10:34 PMInnovent and SanegeneBio Enter Strategic Collaboration to Develop siRNA Drug for the Treatment of Hypertensionfinance.yahoo.com - December 26 at 10:34 PMInnovent and AnHeart Therapeutics Announce the National Medical Products Administration of China Has Granted Taletrectinib (ROS1 Inhibitor) Priority Review Designationfinance.yahoo.com - December 18 at 10:36 PMAnHeart Therapeutics and Innovent Announce China’s NMPA Has Granted Taletrectinib (ROS1 Inhibitor) Priority Review Designationfinance.yahoo.com - December 18 at 12:32 PMInnovent Announces Inclusion in the China National Reimbursement Drug List of TYVYT® 's Seventh Indication and BYVASDA®'s Eighth Indicationfinance.yahoo.com - December 13 at 2:44 AMInnovent Biologics and Synaffix Expand ADC Collaboration Following Positive Preliminary Clinical Signal from Ongoing Phase 1 Studyfinance.yahoo.com - December 7 at 12:42 AMInnovent Announces the Phase 3 ORIENT-16 Study Results Published in JAMA Evaluating Sintilimab in Combination with Chemotherapy for the First-Line Treatment of Gastric or Gastroesophageal Junction (G/GEJ) Adenocarcinomafinance.yahoo.com - December 5 at 8:29 PMInnovent Presents Clinical Data Update of IBI351 (KRAS G12C Inhibitor) Monotherapy in Lung Cancer and Colorectal Cancer at ESMO Asia Congress 2023finance.yahoo.com - November 30 at 11:26 PMInnovent's MSCI ESG Rating Upgraded to Afinance.yahoo.com - November 30 at 8:24 AMInnovent marks China's first regulatory review of a KRAS G12C inhibitormsn.com - November 24 at 10:20 AMChina's First NDA for a KRAS G12C Inhibitor: Innovent Announces the National Medical Products Administration of China Has Accepted and Granted Priority Review Designation to the New Drug Application for IBI351finance.yahoo.com - November 23 at 10:15 PMInnovent Announced China's NMPA Accepts NDA For Taletrectinibmarkets.businessinsider.com - November 22 at 10:41 AMInnovent and AnHeart Therapeutics Announce the National Medical Products Administration of China Has Accepted the New Drug Application for Taletrectinib (ROS1 Inhibitor)finance.yahoo.com - November 22 at 10:41 AMInnovent Presents Clinical Data of Two Ophthalmic Bispecific Antibodies IBI302 (anti-VEGF/complement) and IBI324 (anti-VEGF-A/Ang-2) at American Academy of Ophthalmology (AAO) Annual Meeting 2023finance.yahoo.com - November 5 at 8:17 PMInnovent Biologics Inc 01801morningstar.com - November 1 at 8:31 PMInnovent Announces Robust Weight Loss Efficacy, Multiple Metabolic Benefits and Favorable Safety Profile of Higher Dose 9 mg Mazdutide (IBI362) after 48-week Treatment in Phase 2 Study for Obesityfinance.yahoo.com - October 30 at 12:30 AMInnovent Announces First Patient Dosed in the Phase 3 Clinical Study (STAR) of Efdamrofusp Alfa (IBI302), a First-in-class Ophthalmic Anti-VEGF and Anti-Complement Bispecific Fusion Protein for the Treatment of Neovascular Age-related Macular Degenerationfinance.yahoo.com - October 8 at 11:44 PMInnovent and IASO Bio Present Updated Long-Term Follow-Up Data for BCMA CAR-T FUCASO® (Equecabtagene Autoleucel) at IMS 2023finance.yahoo.com - September 28 at 10:31 PMInnovent Announces 2023 Interim Results and Business Updatesfinance.yahoo.com - August 23 at 9:06 AMInnovent Announces the NMPA Approval of SINTBILO® (Tafolecimab Injection) for the Treatment of Adult Patients with Primary Hypercholesterolemia and Mixed Dyslipidemiafinance.yahoo.com - August 16 at 11:33 PM Get Innovent Biologics News Delivered to You Automatically Sign up to receive the latest news and ratings for IVBXF and its competitors with MarketBeat's FREE daily newsletter. Email Address Never use this word on your phone (FBI could be watching) (Ad)This report sent a chill down my spine. Turns out, as part of their Jan. 6th investigation, the Feds are flagging Americans who typed these ordinary words as part of their banking transactions... Watch my unredacted video about what I think is coming next right here IVBXF Media Mentions By Week IVBXF Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. IVBXF News Sentiment▼0.000.43▲Average Medical News Sentiment IVBXF News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. IVBXF Articles This Week▼11▲IVBXF Articles Average Week Get Innovent Biologics News Delivered to You Automatically Sign up to receive the latest news and ratings for IVBXF and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: AGNPF News Today AKBLF News Today DRTSW News Today ARNI News Today ARTLW News Today ASCLF News Today AWKNF News Today AXIM News Today BRRGF News Today BCTXW News Today Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (OTCMKTS:IVBXF) was last updated on 5/3/2024 by MarketBeat.com Staff From Our PartnersElon to Transform U.S. Economy? Porter & CompanyUrgent Nvidia WarningAltimetryAutomatic Income (from home)Awesomely, LLCGold ManiaStansberry ResearchThe Gold Grab of the CenturyColonial MetalsDid You Get Your Free Bitcoin Yet?Crypto Swap Profits4 Cryptos BETTER than BitcoinTrue Market InsidersJeff Bezos Just Humiliated Elon MuskInvestorPlace Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Innovent Biologics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
